Cepheid Infinity analyser could dramatically reduce turnaround times
The Cepheid Infinity analyser heralds a new era in the delivery
of diagnostic services and collaboration between departments.
In terms of impact, the turnaround of results on patients
screened for Carbapenamase Producing Enterobacteriaceae (CPE)
infection has potentially dropped from around three days to same
day testing within two hours if required.
Manchester Medical Microbiology Partnership (MMMP) has recently
taken delivery of the new instrument, funded by Public Health
This is only the fourth Cepheid Infinity to be placed in the UK
to date, the first outside of London and a first for Public Health
The emergence of CPE and their impact on patients as a Health
Care Acquired Infection (HCAI) has become a serious problem.
The opportunity to utilise rapid screening to effectively manage
the situation was therefore one which couldn't be passed by.
The development of rapid molecular assays for the detection of
CPEs provided a potential resolution to the problem.
Using the experience gained by the Virology Molecular section
over nearly 20 years of initiating and running molecular testing
programs, and a working knowledge of the Cepheid system gained in
Bacteriology running assays for the detection of other bacterial
targets (eg. Clostridium difficile and Mycobacterium
tuberculosis), knowledge and ideas were exchanged to enable
the Cepheid Infinity to make rapid real time testing of numerous
patient samples a reality.
A training program run by Cepheid was supported by means of
competency assessments and induction into the molecular suite in
The Infinity will be operated by staff from Virology and
Bacteriology to deliver rapid screening to aid infection control
and ultimately to provide the opportunity for an out of hours
molecular diagnostics service not currently available.
It is hoped in the near future to further harmonise the approach
taken by both departments and to explore use of the platform to
test for viral infections such as viral meningitis caused by
viruses such as Herpes simplex virus as an On Call service.
Further development of respiratory virus detection to assist
infection control management based on new assays on the Cepheid are
planned to speed diagnosis and treatments of these infections.
Other HCAIs such as Norovirus are also scheduled to receive
benefits of more accessible rapid diagnostic testing leading to
further patient benefits in the near future
Additionally, both the Virology and Bacteriology departments
were also able to benefit from an efficiency evaluation (LEAN)
performed by the supplier to further enhance the performance of
their processes supported by the Cepheid technology.
It is hoped that this continuing collaboration will reap further
benefits in the future as new developments come on stream.